<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1012-2966</journal-id>
<journal-title><![CDATA[Gaceta Médica Boliviana]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Med Bol]]></abbrev-journal-title>
<issn>1012-2966</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Medicina de la Universidad Mayor de San Simón]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1012-29662022000100029</article-id>
<article-id pub-id-type="doi">10.47993/gmb.v45i1.382</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticuerpos Anti SARS-CoV-2, Post-vacunación en Cochabamba, Bolivia]]></article-title>
<article-title xml:lang="en"><![CDATA[Post-vaccination Anti SARS-CoV-2 Antibodies in Cochabamba, Bolivia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Limachi Choque]]></surname>
<given-names><![CDATA[Jhonny Wilson]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Verduguez-Orellana]]></surname>
<given-names><![CDATA[Aleida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Corporación del Seguro Social Militar (COSSMIL) Unidad de Epidemiologia ]]></institution>
<addr-line><![CDATA[Cochabamba ]]></addr-line>
<country>Bolivia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Mayor de San Simón Facultad de Medicina Centro Universitario de Medicina Tropical (CUMETROP)]]></institution>
<addr-line><![CDATA[Cochabamba ]]></addr-line>
<country>Bolivia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Mayor de San Simón Facultad de Medicina Centro Universitario de Medicina Tropical (CUMETROP)]]></institution>
<addr-line><![CDATA[Cochabamba ]]></addr-line>
<country>Bolivia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>45</volume>
<numero>1</numero>
<fpage>29</fpage>
<lpage>35</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1012-29662022000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1012-29662022000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1012-29662022000100029&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los anticuerpos neutralizantes (NAbs) contra el SARS-CoV-2 están siendo evaluados en humanos. Las respuestas adaptativas específicas de los sujetos asintomáticos o sintomáticos contra el antígeno de SARS-CoV-2, presentan una correlación positiva con la respuesta inmunitaria humoral.  Objetivo:  evaluar la presencia de anticuerpos contra la proteína específica de la espiga (RBD, dominio de unión al receptor de la proteína de espícula) y NP (nucleoproteína) del virus SARS-CoV-2 en personas que recibieron vacunas anti COVID-19 empleadas en Bolivia.  Métodos:  durante el año 2021 entre los meses de julio y agosto, se realizó un estudio observacional de tipo transversal, en 150 personas de ambos sexos que fueron reclutadas en los Hospitales: Caja de Seguro Social Militar y Caja Nacional de Salud, para detectar anticuerpos específicos contra las proteínas NP y RBD del virus SARS-CoV-2 responsable de la COVID-19, mediante una prueba inmunocromatográfica cualitativa.  Resultados:  la presencia de anticuerpos neutralizantes posterior a la aplicación de vacunas contra SARS-CoV-2, como esquema completo, primera dosis, y/o el antecedente de infección, se encontró en el 61 % de las personas agrupadas en la categoría "bajo riesgo laboral&#8221; de forma heterogénea en lo referente a anticuerpos RBD, NP o ambas juntas.  Conclusiones: la producción de anticuerpos contra la proteína específica de la espiga RBD y NP del virus SARS-CoV-2 muestra una respuesta heterogénea por varios factores como ser, tipo de vacuna, numero de dosis, infección por el COVID-19, disminución de anticuerpo a largo del tiempo, sensibilidad del test y las propiedades intrínsecas de la persona evaluada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Neutralizing antibodies (NAbs) against SARS-CoV-2 are being evaluated in humans. The specific adaptive responses of asymptomatic or symptomatic subjects against SARS-CoV-2 antigen show a positive correlation with the humoral immune response.  Objective:  To evaluate the presence of antibodies against spike specific protein (RBD, receptor binding domain of spike protein) and NP (nucleoprotein) of SARS-CoV-2 virus in people who received anti-COVID-19 vaccines used in Bolivia.  Methods:  During 2021 between July and August, a cross-sectional observational study was carried out in 150 persons of both sexes who were recruited in the Hospitals: Caja de Seguro Social Militar and Caja Nacional de Salud, to detect specific antibodies against the NP and RBD proteins of the SARS-CoV-2 virus responsible for COVID-19, by means of a qualitative immunochromatographic test.  Results:  The presence of neutralizing antibodies after the administration of vaccines against SARS-CoV-2, as complete scheme, first dose, and/or history of infection, was found in 61 % of the persons grouped in the category "low occupational risk" in a heterogeneous way regarding RBD antibodies, NP or both together.  Conclusions:  The production of antibodies against the specific protein of the RBD and NP spike of the SARS-CoV-2 virus shows a heterogeneous response due to several factors such as, type of vaccine, number of doses, infection by COVID-19, antibody decline over time, sensitivity of the test and intrinsic properties of the person evaluated.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos]]></kwd>
<kwd lng="es"><![CDATA[vacunas]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[antibodies]]></kwd>
<kwd lng="en"><![CDATA[vaccines]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wajnberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amanat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Firpo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Robust neutralizing antibodies to SARS-CoV-2 infection persist for months]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lilly]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and. 2020]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ajithdoss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Copin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Jette]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Abernathy]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Characteristics of Coronavirus Disease 2019 in China]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maggi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Capone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients]]></article-title>
<source><![CDATA[Eur J Immunol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sette]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Crotty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adaptive immunity to SARS-CoV-2 and COVID-19]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picazo]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vacuna frente al COVID-19]]></article-title>
<source><![CDATA[Rev Española Quimioter]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<source><![CDATA[Vacunas contra la COVID-19]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Deportes de Bolivia</collab>
<source><![CDATA[Conozca las características de las vacunas que llegan a Bolivia para luchar contra la COVID-19]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<source><![CDATA[Sputnik V: ¿por qué la OMS no ha autorizado aún su uso de emergencia?]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Charca-Rodríguez]]></surname>
<given-names><![CDATA[FDM]]></given-names>
</name>
<name>
<surname><![CDATA[Pareja-Medina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la respuesta humoral inducida por la vacuna BBIBP-CorV mediante la determinación de anticuerpos neutralizantes en personal sanitario peruano]]></article-title>
<source><![CDATA[Rev Per Med Exp Sal Púb]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaus]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19: vacunas]]></article-title>
<source><![CDATA[Práctica Fam Rural]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairoli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loubet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Laureillard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why promoting a COVID-19 vaccine booster dose?]]></article-title>
<source><![CDATA[Anaesth Crit Care Pain Med]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Widge]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Rouphael]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doria-Rose]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suthar]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Makowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Favresse]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bayart]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Mullier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody titres decline 3-month post-vaccination with BNT162b2]]></article-title>
<source><![CDATA[Emerg Microbes Infect]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Sahly]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Baden]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Essink]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andrée]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moskorz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Infectious Diseases Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Lustig]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lara-Sanjuan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Parra-Ortega]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Pérez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de una prueba rápida versus un inmunoanálisis quimioluminiscente de micropartículas para la detección de anticuerpos contra SARS-CoV-2]]></article-title>
<source><![CDATA[Rev Mex Patol Clínica y Med Lab]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mekonnen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mengist]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Derbie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Rev Med Virol]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kopel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Perisetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roghani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Racial and Gender-Based Differences in COVID-19]]></article-title>
<source><![CDATA[Front Public Heal]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Rosa-Bray]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Staats]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Premkumar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia-Chumbez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jadi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Raut]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Markmann]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients]]></article-title>
<source><![CDATA[Sci Immunol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
